Patients hoping for a new alternative to the blockbuster blood thinner Plavix will have to wait a bit longer for a verdict on a promising candidate.
Global Cancer Consortium
ZymoGenetics Acquisition Highlights Competitive Hepatitis C Treatment Race
Bristol-Myers Squibb Company (BMS) announced Tuesday that it had signed an agreement to acquire biopharmaceutical company ZymoGenetics for approximately $885 million, or $9.75 per share in cash.
Guiding Life Sciences Companies Along the Path to Success
Operating for over 50 years, Safeguard Scientifics is a holding company that provides capital, as well as strategic, operational and management resources for technology and life sciences companies.
Growing Regenerative Medicine Market Provides Opportunities for Cytori Therapeutics
For many breast cancer patients, the effects of undergoing a mastectomy go well beyond the physical.
Market for Incontinence Products, Therapies Expected to Grow
Advances in medicine have allowed people in developed countries to live longer, but at a cost: An increased lifespan raises a patient’s likelihood of developing health issues such as angina or incontinence.
The Ambitious Pipeline of EpiCept Corporation
EpiCept’s lead product, Ceplene, is approved for marketing in the EU for the maintenance of first remission in patients with acute myeloid leukemia.
Ascalon Leverages Experienced Management Team, Strategic Partnerships for Cancer Drug Development
Ascalon International is a privately held oncology-focused drug development company based in Scottsdale, Arizona.
AesRx Aims at Two Rare Diseases In Growing Orphan Drug Market
The Newton, Mass.-based biopharmaceutical company is developing a small-molecule drug for sickle cell disease.
